YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
ImmunityBio IBRX shares soared 7% in the last trading session to close at $8.46. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.7% loss over the past four we…
PDS Biotechnology Corporation Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PD…
PDS Biotechnology (NASDAQ:PDSB) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings call transcrip…
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is projected to report earnings for its first quarter…
* PDS Biotechnology (PDSB [https://seekingalpha.com/symbol/PDSB]) is scheduled to announce Q1 earnings results on Wednesday, May 13th, before market open. * The consensus EPS Estimate is -$0.14 [https://seekingalpha.com/symbol/PDSB/earning…
(RTTNews) - PDS Biotechnology Corporation (PDSB) announced positive interim Phase 2 results from Stage 1 of an NCI-led trial evaluating its tumor-targeted IL-12 immunocytokine, PDS01ADC, in patients with metastatic colorectal cancer (mCRC)…
Earnings Call Insights: PDS Biotechnology Corporation (PDSB) Q4 2025 MANAGEMENT VIEW * Frank Bedu-Addo, President, CEO & Director, detailed that "the fourth quarter of 2025 capped a period of important progress for PDS Biotech, marked by m…
Major earnings expected before the bell on Monday include: * Fermi (FRMI [https://seekingalpha.com/symbol/FRMI]) * Sigma Lithium Corporation (SGML [https://seekingalpha.com/symbol/SGML]) * Rezolve AI PLC (RZLV [https://seekingalpha.com/sym…
* PDS Biotechnology (PDSB [https://seekingalpha.com/symbol/PDSB]) is scheduled to announce FY earnings results on Monday, March 30th, after market close. * The consensus EPS Estimate is -$0.80 [https://seekingalpha.com/symbol/PDSB/earnings…
[Nest of Eggs] LindaJoHeilman As the calendar turns from March to April, a holiday-shortened week still delivers a diverse set of earnings with the potential to offer fresh directional cues. Consumer and brand momentum will be in focus wit…
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or t…
PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, t…
B. Riley lowered the firm’s price target on PDS Biotechnology (PDSB) to $3 from $5 and keeps a Buy rating on the shares. The shares remain attractively valued with near-zero EV that fails to reflect impact of this recent strategic pivot on…
* PDS Biotechnology press release [https://seekingalpha.com/pr/20305887-pds-biotech-reports-third-quarter-2025-financial-results-and-provides-clinical-programs] (PDSB [https://seekingalpha.com/symbol/PDSB]): Q3 GAAP EPS of -$0.19 beats by…
Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval Pathway in Ongoing VERSATILE-003 Pha…
Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics that make them more active in killing ca…
Company aims to shorten time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer, projected to be the most dominant type of head and neck cancer in the US by mid 2030s Proposed Amendment to Ongoing VERSATIL…
First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients with CPS 1-19* Encouraging efficacy sig…
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3 trial in progress PRINCETON, N.J., Aug.…
PDS Biotechnology Corp (PDSB) reported a narrower-than-expected loss in its second quarter earnings for 2025, with an EPS of -$0.21, slightly beating the forecast of -$0.22. The company’s stock responded positively, showing a premarket inc…
PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB [https://www.chartmill.com/stock/quote/PDSB/profile]) reported its second-quarter 2025 financial results, with earnings per share (EPS) of -$0.21, slightly better than the analyst consensus estimate of -…
* PDS Biotechnology press release [https://seekingalpha.com/pr/20199124-pds-biotech-reports-second-quarter-2025-financial-results-and-provides-clinical-programs] (NASDAQ:PDSB [https://seekingalpha.com/symbol/PDSB]): Q2 GAAP EPS of -$0.21 b…
Major earnings expected before the bell on Wednesday include: * Tencent Holdings Limited (OTCPK:TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Stratasys Ltd. (SSYS [https://seekingalpha.com/symbol/SSYS]) * Organigram Global (OGI [https:/…
Investing.com - PDS Biotechnology Corp (NASDAQ:PDSB), currently valued at $59.4 million, has completed patient recruitment for Stage 1 of a clinical trial evaluating its PDS01ADC therapeutic in metastatic colorectal cancer (mCRC), meeting…
Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe Webinar to be held Tuesday, June 17, 2025, 12:00 PM ET PR…
Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 is 30.0 months Phase 3: Versamune® HPV with pembrolizumab as 1…
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, to…
PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, to…
PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers,…
PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers,…
NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage im…
Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnolo…
PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers,…
NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now availabl…
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap…
PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers,…